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Objective: Botulinum toxin type A (BoNT-A) injections are recommended for the management of upper limb 
spasticity (ULS) and cervical dystonia (CD). The main aim of this cost minimization analysis (CMA) was to compare 
the annual cost per patient for three BoNT-As (Botox®, Dysport® and Xeomin®) in the treatment of ULS or CD in 
Italy. A budget impact analysis (BIA) was also conducted.
Methods: The CMA was conducted from the perspective of the Italian National Health Service. Only direct medi-
cal costs (BoNT-A and standard therapy) were considered. By using a Delphi panel of twelve Italian Experts in the 
treatment of ULS and CD, data was collected about BoNT-As (dose, number of administrations and acquisition 
price) and standard therapy (concomitant medications, visits, Day-Hospital, hospitalizations, etc.). Costs were as-
sessed in Euros 2014. The BIA was conducted to evaluate the pharmaceutical expenditure for the three BoNT-As 
on a five-year time horizon. A sensitivity analysis was conducted.
Results: The mean annual cost per patient with ULS was €1,840.20 with Dysport®, €2,067.12 with Botox® and 
€2,171.05 with Xeomin®. The mean annual cost per patient with CD was €1,353.79 with Dysport®, €1,433.12 
with Botox® and €1,503.60 with Xeomin®. In the time horizon considered, the substitution process of Botox® and 
Xeomin® by Dysport® would result in a total saving of €620,000 when treating ULS and a total saving of €481,000 
in the case of CD. Sensitivity and probabilistic analyses showed the robustness of results.
Conclusions: From the Italian National Health Service’s perspective, Dysport® appears to be the cost-saving ther-
apeutic option compared with Botox® and Xeomin® in the treatment of ULS or CD.
Keywords: BoNT-A, Cervical dystonia, Cost-minimization analysis, Upper limb spasticity
Introduction
Botulinum toxin type A (BoNT-A) is recommended as 
pharmacological treatment, along with physical therapy and 
postural control management, in the treatment of upper limb 
spasticity (ULS) and cervical dystonia (CD) (1-4).
When injected in the muscle, botulinum toxin acts 
pre- synaptically blocking the release of acetylcholine 
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neurotransmitter in the neuromuscular junction, causing 
a reduction of the contraction force (5). This action allows 
the muscles to relax, restoring normal posture. The use of 
BoNT-As is frequently associated with a significant improve-
ment in patients’ health conditions (pain intensity, muscle 
tone, lessened disability) and quality of life (4, 6-12).
The main formulations of BoNT-A currently available in 
Italy are Botox® (Allergan SpA), Dysport® (Ipsen SpA) and Xe-
omin® (Merz Pharma Italia srl). The respective authorizations 
for use in the treatment of ULS and CD have been obtained 
by submitting to the competent Agency three different reg-
istration dossiers, each drawn up in the form of a Full Appli-
cation, i.e. presenting the results of pharmaceutical studies, 
preclinical studies and clinical trials. As a result of these three 
different registration dossiers Botox®, Dysport® and Xeomin® 
constitute three distinct originator drugs (13).
Apart from the regulatory aspects, the three BoNT-As are 
also characterized by significant differences in terms of man-
ufacturing process, efficacy, distribution (persistence in the 
application site) and dose-response curve, as well as in struc-
ture, molecular weight, excipients, purification processes and 
storage methods (14-16). Because of these differences, the 
units of each BoNT-A are not interchangeable and the num-
ber of units recommended for each indication is specific for 
each preparation (17). Thus, the clinician’s choice in deter-
mining which BoNT-A to administer is often complex.
As efficacy and tolerability seem to be strictly dose-de-
pendent (8-11, 18-21), in a perspective of containment of 
pharmaceutical expenditure, the simultaneous presence of 
three different pharmacological alternatives for the treat-
ment of ULS or CD determines the need to provide, in support 
of clinicians’ decision-making process, at least an estimate of 
their economic impact on the Italian National Health Service 
(INHS). Pursuing this objective, this economic assessment 
was conducted to evaluate which BoNT-A (Botox®, Dysport® 
or Xeomin®) determines the most efficient allocation of the 
economic resources available to the INHS in the treatment of 
ULS and CD. Additionally, for the purpose of estimating the 
impact of these choices on pharmaceutical expenditure, a 
Budget Impact Analysis (BIA) was conducted (22).
Methods
Analysis technique 
Since it seems to be more appropriate to speak of dif-
ferences in dosages rather than in efficacy and tolerability 
(8-11, 17-20), we chose to conduct this comparison in the 
form of a Cost Minimization Analysis (CMA) and to focus solely 
on the costs of treatment associated with the use (dosage) of 
the three botulinum toxins type A.
Study design
Cost minimization analysis 
The comparison between the botulinum toxins – expressed 
in terms of average annual cost per treated patient – was made 
possible through the development of an Excel® model. The 
CMA was conducted from the INHS’s perspective, considering 
solely the direct medical costs such as botulinum therapy and 
standard therapy. The latter consists of concomitant drugs (an-
ticholinergics, anticonvulsants, analgesics, etc.), interventions 
by specialists (neurologist, physical therapist, physiatrist, etc.), 
rehabilitation therapies (electromiography, electrostimulation, 
ultrasound, etc.) and other healthcare services (Day-Hospital, 
hospitalizations, CT scans, etc.). The cost estimate refers to 
2014, while the analysis time horizon is 12 months, commen-
surate to the objective of estimating an average annual cost 
per patient. 
Budget impact analysis
The budget impact analysis has been conducted with the 
objective of building a scenario representing the five-year 
evolutionary trend of pharmaceutical expenditure for the 
three botulinum toxins. This was done using: 
– cost data associated to pharmacological treatment with 
BoNT-A only, 
– available epidemiological data to estimate the size of the 
cohorts of patients with ULS or CD eligible for treatment 
with BoNT-A, and
– the market shares of the three BoNT-As (estimated on 
the basis of the number of vials purchased in the last six 
months by healthcare facilities).
The estimate of the number of patients with ULS or CD 
eligible for treatment with BoNT-A in the five-year period 
was carried out according to a rather complex process. The 
starting point was the determination of the general popula-
tion in the first year of analysis, corresponding to the resident 
Italian population on 1 January 2013 (ISTAT data). The evolu-
tion of the size of the general population over the next four 
years was determined by applying a constant average annual 
growth rate of 0.49%; this rate was calculated as a ratio of the 
resident Italian population on 1 January 2012 to the resident 
population on 1 January 2013.
The cohort of patients with CD eligible for treatment with 
BoNT-A was determined by applying to the general popula-
tion, for each of the five years, a constant prevalence rate of 
cervical dystonia of 0.01375% (23); it was then assumed that 
only 84% of these patients could be treated with one of the 
three BoNT-As (24). 
The second cohort of patients eligible for treatment with 
BoNT-A was estimated considering stroke as the only cause 
of ULS. First, a prevalence rate (1.47%) was applied to the 
general population to estimate the number of subjects with 
stroke (24). Subsequently, the number of subjects with stroke 
who could develop ULS was estimated (17% of the population 
with stroke). Lastly, it was assumed that 2.45% of these could 
be treated with a BoNT-A (24).
The two cohorts of patients estimated as described 
above were then subdivided according to their respective 
market shares: the number of patients receiving treatment 
with Botox®, Dysport® and Xeomin® year by year was thus 
determined. The market shares for the two investigated in-
dications were estimated by a group of experts (see section 
“Healthcare resources and unit costs”). In the base scenario 
(Scenario A) market shares remained constant for all five 
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o  the average number of healthcare services provided 
during the year, and 
o the unit cost; 
– for rehabilitation therapies (electromyography, electro-
stimulation, etc.) and other healthcare services (hospi-
talizations, Day-Hospital, etc.) 
o the average percentage of use per patient, 
o  the average number of healthcare services provided 
during the year, and 
o the unit cost. 
Consumptions related to concomitant pharmacological 
treatments were calculated on the basis of the respective pur-
chase prices paid by the INHS, while all the other consump-
tion items considered in the questionnaires were determined 
as average costs calculated on the basis of the unit costs (re-
gional tariffs) indicated by the experts. In the second section 
of the questionnaire, the data collection was structured so as 
to exclude the possibility of differentiating standard treatment 
consumptions according to the administered botulinum toxin, 
and therefore assuming equal costs for Botox®, Dysport® and 
Xeomin®.
Lastly, in the third section of the case report form (CRF), 
in order to determine market shares necessary to conduct 
the BIA, the experts were asked to indicate (on the basis of 
the vials purchased by the hospital pharmacy in the last six 
months) the average consumption percentage for Dysport®, 
Botox® and Xeomin® in their respective centres.
In accordance with the Delphi methodology, the complet-
ed questionnaires were processed and prepared in the form 
of a first summary of results (first round), and submitted to a 
subsequent evaluation by the experts. Specifically, in this sec-
ond round, the experts were asked to confirm or correct the 
data entered in their questionnaire, comparing them against 
those presented in the summary document. The values indi-
cated by the experts on the first summary document (second 
round) were then set out as final data collection document. 
The average time provided for completion of the question-
naires and subsequent re-analysis was one month for each of 
the two rounds. 
Sensitivity analysis
A series of univariate one-way analyses were conducted 
in order to evaluate the validity of the results of the Cost 
 Minimization Analysis and Budget Impact Analysis base case 
in response to changes in the values of the parameters used. 
Specifically, in the univariate analysis the average base case 
values were changed one at a time with the respective median 
values for the dose per treatment, the time to next treatment 
and the cost per vial. As the vials price was also determined 
on the basis of information provided by the experts, it was 
deemed appropriate to repeat the CMA and the BIA replac-
ing the base-case average price per vial with the ex-factory 
price net of the discounts required by law  (Botox®: €129.05 
for a 100 U vial; Dysport®: €175.32 for a 500 U vial; Xeomin®: 
€129.05 for a 100 U vial). Lastly, with reference to the BIA 
only, two additional scenarios were presented in which the 
effect of the substitution by Dysport® was increased to 8 and 
12 percentage points per year. 
years. However, because the objective of the BIA was to de-
termine the economic impact resulting from a greater use 
of botulinum toxin with the lowest average annual cost per 
patient, a new scenario was created (Scenario B), different 
from the base case, in which the market share of Dysport® 
increased compared to those of the other two BoNT-As, 
which instead decreased proportionally. In building Scenario 
B, the annual substitution effect of Dysport® was assumed 
to be 6 percentage points, balanced by an equal reduction 
of 3 percentage points for each of the other two toxins. 
Healthcare resources and unit costs
To determine the healthcare resources used by patients 
with ULS and CD, and the respective unit costs, a group of 
experts were administered two questionnaires, one for up-
per limb spasticity and the other for cervical dystonia, specifi-
cally prepared by a board consisting of two leading experts. 
These data were collected using the Delphi technique, based 
on a structured interaction between experts and researchers 
(25, 26). First, a series of experts was identified on the ba-
sis of the following criteria: i) representative of the national 
territory, and ii) long-standing experience in the treatment of 
ULS and/or CD. These experts were then contacted via e-mail 
to explain the purposes and methodology of the data collec-
tion process, and to inquire about their willingness to partici-
pate. All the twelve experts who were contacted accepted to 
participate in the data collection project.
Each of the experts who confirmed their participation was 
sent two electronic questionnaires (ULS and CD) structured 
for data collection. The questionnaires were subdivided into 
three sections: the first and second sections were aimed at 
collecting data to determine the average annual cost per pa-
tient, while the third section was designed to estimate the 
market shares of the three BoNT-As (Budget Impact Analysis). 
In the first section, the experts were asked to indicate for each 
of the three BoNT-As – based on their experience with the 
patients treated in their centres – the average dose per treat-
ment (expressed in units, U), the average number of weeks 
to the next treatment, and the cost incurred by the hospital 
pharmacy (ex-factory price net of mandatory discounts and 
any additional discounts granted by the marketing authoriza-
tion [MA] holder to the healthcare facilities) to purchase one 
500 U vial of Dysport®, one 100 U vial of Botox®, and one 
100 U vial of Xeomin®. The selected dose units are those most 
commonly used in clinical practice. A scenario without drug 
wastage (full utilization of vial contents) has been considered 
to evaluate the cost of treatment of the three BoNT-As. In 
the second section, aimed at collecting data on healthcare 
resources used by standard treatment, to be added to the 
costs of botulinum toxin, the experts were asked to indicate:
– for the concomitant pharmacological therapy (anticon-
vulsants/analgesics, myorelaxants and other drugs)
o the average percentage of use per patient, 
o the average dose per day of treatment, and 
o the average number of days per month of treatment; 
– for specialist interventions (physiatrist, physical therapist, 
neurologist, etc.) 
o the average percentage of use per patient, 
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Tables IV and V provide details, for ULS and CD respectively, 
of the average dose administered per treatment, the average 
number of weeks between treatments, the average cost per 
vial and the average cost per session (dose administered per 
treatment) of Dysport®, Botox® and Xeomin®.
With reference to the average cost of standard therapy 
in the treatment of ULS, specialist interventions account 
for the greatest portion (49.6%), followed by rehabilitation 
therapies (24.7%), concomitant drugs (14.8%) and other 
healthcare services (11.0%) (Fig. 1). Over 90% of the cost of 
specialist interventions is taken up by physical therapy ses-
sions. Botulinum toxin injections cover approximately 60% 
of the total cost of rehabilitation therapies, while among 
Results 
The distribution by geographic area (North, Centre, South 
and Islands) of the experts participating in the data collec-
tion reflects that of the Italian population, with minimal de-
viations (Tab. I). All twelve experts who were consulted com-
pleted the respective questionnaires concerning upper limb 
spasticity, while the percentage of completion of the cervical 
dystonia questionnaires was 83% (10 out of 12) because two 
experts included did not treat patients for this indication. 
CMA results 
Tables II and III present the detailed results of the compar-
ison between the three botulinum toxins type A (Dysport®, 
Botox® and Xeomin®) expressed in terms of average annual 
cost per treated patient. For both the indications considered, 
upper limb spasticity and cervical dystonia, Dysport® was 
associated with the lowest annual average cost per treated 
patient. The difference compared to Botox® and Xeomin® is 
more significant in the management of ULS (ULS: -€226.88 
compared to Botox® and -€330.81 compared to Xeomin®; 
CD: -€79.34 compared to Botox® and -€149.82 compared to 
Xeomin®). As the standard therapy was assumed to be the 
same for all three BoNT-As, the differences in average treat-
ment costs are attributable solely to the administered botu-
linum therapy. 
TABLE I -  Geographic distribution of experts participating in data 
collection
Geographic areas Experts Italian population
(× 1,000)*
no. % no. %
North 6 50% 27,383 46%
Centre 2 17% 11,681 20%
South and Islands 4 33% 20,621 34%
Total 12 100% 59,685 100%
*Resident population at January 1, 2013.
TABLE II - Average annual cost per treated patient: ULS
Upper limb spasticity
Cost drivers Dysport® Botox® Xeomin®
Botulinum toxin €700.63 €927.51 €1,031.44
Standard treatment €1,139.61 €1,139.61 €1,139.61
 - concomitant drugs €168.27 €168.27 €168.27
 - specialists €565.11 €565.11 €565.11
 - rehabilitation therapies €281.20 €281.20 €281.20
 - other healthcare services €125.03 €125.03 €125.03
Total €1,840.24 €2,067.12 €2,171.05
Difference vs Dysport®  +€226.88 +€330.81
TABLE III - Average annual cost per treated patient: CD
Cervical dystonia
Cost drivers Dysport® Botox® Xeomin®
Botulinum toxin €668.87 €748.20 €818.68
Standard treatment €684.92 €684.92 €684.92
 - concomitant drugs €136.07 €136.07 €136.07
 - specialists €135.44 €135.44 €135.44
 - rehabilitation therapies €374.72 €374.72 €374.72
 - other healthcare services €38.68 €38.68 €38.68
Total €1,353.79 €1,433.12 €1,503.60
Difference vs Dysport®  +€79.34 +€149.82
TABLE IV -  Average dose, average time to next treatment and aver-
age cost per vial: ULS
Upper limb spasticity
Botulinum therapy Dysport® Botox® Xeomin®
Average dose per session (U) 661 218 263
 - median 580 227 264
 - std. dev. 290 73 76
 - min 348 100 120
 - max 1350 360 350
Time to next treatment  
(no. of weeks) 15.3 14.7 14.6
 - median 16.0 15.4 14.9
 - std. dev. 2.5 2.8 2.9
 - min 10.0 10.0 11.0
 - max 18.2 18.4 18.3
Average cost per vial (€) €155.54 €120.14 €110.17
 - median €147.68 €117.54 €113.85
 - std. dev. €16.13 €4.99 €10.97
 - min €140.00 €116.14 €95.45
 - max €175.33 €129.05 €122.80
Average cost per session (€) €205.62 €261.91 €289.75
U = Unit.
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Budget impact analysis
On the basis of epidemiological data (number of subjects 
with ULS or CD treated with BoNT-A), market shares (experts’ 
estimate) and pharmacological costs of botulinum toxins 
(CMA estimate), we calculated the pharmacological expendi-
ture for BoNT-As incurred by the IHNS over the five years of 
observation. 
Tables VI and VII show the results of the analysis conduct-
ed for ULS and CD, respectively; in both cases, a comparison 
is carried out between two specific scenarios (Scenario A and 
Scenario B), differentiated solely by the considered market 
shares. In Scenario A (both for ULS and for CD) the market 
share estimated by the experts was kept constant over the 
observation period (ULS: Dysport® 45%, Botox® 28% and 
Xeomin® 27%; CD: Dysport® 39%, Botox® 28% and Xeomin® 
33%), while in Scenario B the market share was changed from 
the second year onward by applying a Dysport® substitution 
effect of 6 percentage points per year, equally distributed 
between Botox® (minus 3 percentage points) and Xeomin® 
(minus 3 percentage points). During the five year period, Dys-
port® would rise from a 45% share in the first year to a 69% 
share in the fifth year in the treatment of ULS, and from 39% 
in the first year to 63% in the fifth year in the treatment of CD. 
With these trends in the market shares of Dysport® the over-
all reduction of the pharmaceutical expenditure incurred by 
the INHS over the five year period would amount to €620,428 
for ULS and to €480,918 for CD (Fig. 3).
One-way sensitivity analysis
The sensitivity analysis confirmed the validity of the re-
sults of the CMA and BIA base case to changes in the main 
parameters considered (dose per treatment, time to next 
treatment and cost per vial) (Tabb. VIII and IX).
In ULS, the parameter that most influences the com-
parison between Dysport® and Botox® is the median dose 
(54% change compared to base case); in the comparison 
between Dysport® and Xeomin® the result is influenced in 
equal proportions by median dose (28% change compared 
to base case), median cost (21% change compared to base 
concomitant drugs myorelaxants account for 90% of the ex-
penditure.
In cervical dystonia, the main cost related to standard 
treatment is represented by rehabilitation therapies (54.7%), 
followed by concomitant drugs (19.9%), specialist interven-
tions (19.8%), and other healthcare services (5.6%) (Fig. 2). 
Here again, the highest percentage (approximately 80%) of 
the costs related to rehabilitation therapies is attributable to 
botulinum toxin injection. Neurologist and physical therapist 
interventions (47% and 48%, respectively) account for over 
90% of the costs of specialists. Lastly, among concomitant 
drugs, approximately 60% of the costs is due to neuroleptics.
Fig. 2 - Standard cervical dystonia (CD) treatment: incidence of cost 
drivers.
TABLE V -  Average dose, average time to next treatment and aver-
age cost per vial: CD
Cervical dystonia
Botulinum therapy Dysport® Botox® Xeomin®
Average dose per session (U) 538 148 178
 - median 562 142 180
 - std. dev. 145 48 50
 - min 326 80 90
 - max 750 245 245
Time to next treatment  
(no. of weeks) 12.7 12.4 12.2
 - median 12.3 12.2 12.0
 - std. dev. 1.5 1.6 1.5
 - min 10.0 10.0 10.0
 - max 15.0 15.0 15.0
Average cost per vial (€) €151.58 €120.20 €107.90
 - median €145.23 €117.54 €104.50
 - std. dev. €14.62 €5.23 €10.59
 - min €140.00 €116.14 €95.45
 - max €175.33 €129.05 €121.08
Average cost per session (€) €163.10 €177.90 €192.06
U = Unit.
Fig. 1 - Standard upper limb spasticity (ULS) treatment: incidence 
of cost drivers.
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most  heavily influences the final result (ULS: 38% change; 
CD: -36% change).
Over the five year period, with a substitution effect of 
8 percentage points, in the treatment of ULS Dysport® would 
reach a market share of 77%, generating an overall reduc-
tion in botulinum toxin expenditure of €0.8 million; in the 
treatment of CD, the market share would be approximately 
71% and the reduction in toxin expenditure would amount 
to €650,000. With a substitution effect of 12 percentage 
case) and ex-factory price per vial (26% change compared 
to base case). For CD, in the comparison against Botox® the 
median dose (-76% change compared to base case) and ex-
factory price (-63% change compared to base case) are the 
parameters that most characterize the variability of results. 
In the comparison against Xeomin®, the ex-factory price of 
vials is the only variable that significantly modifies the final 
result (37% change compared to base case). In the Budget 
Impact Analysis, the median dose is the parameter that 
TABLE VI - Budget Impact Analysis (BIA) results: ULS
Upper limb spasticity
BoNT-A cost First year Second year Third year Fourth year Fifth year
No.  
of pts
3,654 No.  
of pts
3,672 no.  
of pts
3,690 no.  
of pts
3,708 No.  
of pts
3,726
MS* Expenditure (€) MS Expenditure (€) MS Expenditure (€) MS Expenditure (€) MS Expenditure (€)
Dysport® €701 45% 1,152,120 45% 1,157,765 45% 1,163,438 45% 1,169,138 45% 1,174,867
Botox® €928 28% 949,018 28% 953,668 28% 958,341 28% 963,037 28% 967,755
Xeomin® €1,031 27% 1,017,670 27% 1,022,656 27% 1,027,667 27% 1,032,702 27% 1,037,762
Scenario A 100% 3,118,807 100% 3,134,089 100% 3,149,445 100% 3,164,877 100% 3,180,384
Dysport® €701 45% 1,152,120 51% 1,312,134 57% 1,473,688 63% 1,636,794 69% 1,801,462
Botox® €928 28% 949,018 25% 851,489 22% 752,982 19% 653,489 16% 553,003
Xeomin® €1,031 27% 1,017,670 24% 909,028 21% 799,296 18% 688,468 15% 576,535
Scenario B 100% 3,118,807 100% 3,072,650 100% 3,025,966 100% 2,978,751 100% 2,931,000
Difference B-A  0  -61,439  -123,479  -186,126  -249,384
*Estimate provided by experts.
MS = market share; pts = patients. 
TABLE VII - Budget Impact Analysis (BIA) results: CD
Cervical dystonia
BoNT-A cost First year Second year Third year Fourth year Fifth year
No.  
of pts
6,894 No.  
of pts
6,927 No.  
of pts
6,961 No.  
of pts
6,995 No.  
of pts
7,030
MS* Expenditure (€) MS Expenditure (€) MS Expenditure (€) MS Expenditure (€) MS Expenditure (€)
Dysport® €669 39% 1,798,262 39% 1,807,073 39% 1,815,928 39% 1,824,825 39% 1,833,767
Botox® €748 28% 1,444,199 28% 1,451,275 28% 1,458,386 28% 1,465,532 28% 1,472,713
Xeomin® €819 33% 1,862,425 33% 1,871,550 33% 1,880,720 33% 1,889,935 33% 1,899,196
Scenario A 100% 5,104,885 100% 5,129,898 100% 5,155,034 100% 5,180,292 100% 5,205,675
Dysport® €669 39% 1,798,262 45% 2,085,085 51% 2,374,675 57% 2,667,052 63% 2,962,238
Botox® €748 28% 1,444,199 25% 1,295,781 22% 1,145,875 19% 994,468 16% 841,550
Xeomin® €819 33% 1,862,425 30% 1,701,409 27% 1,538,771 24% 1,374,498 21% 1,208,579
Scenario B 100% 5,104,885 100% 5,082,275 100% 5,059,320 100% 5,036,019 100% 5,012,367
Difference B-A  0  -47,623  -95,713  -144,274  -193,307
*Estimate provided by experts. 
MS = market share; pts = patients. 
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Discussion
The results estimated by the Cost Minimization  Analysis 
indicate Dysport® to be the cost-saving alternative in the 
treatment of upper limb spasticity and cervical dystonia com-
pared to Botox® (ULS: -€226.88; CD: -79.34) and Xeomin® 
(ULS: -€330.81; CD: -149,82). At national level (Budget Impact 
 Analysis), these differences in cost could result in a reduction in 
pharmaceutical expenditure for botulinum toxins, which would 
be more or less significant depending on the level of use (sub-
stitution rate) of Dysport® compared to the other two BoNT-As.
As the calculation of the average cost per treated patient 
is based solely on a data collection process that involved 12 
experts, it was in our opinion extremely important to verify, 
first and foremost, whether the cost estimated in this docu-
ment were comparable with those of other studies. Weight-
ing the average costs of treatment of the three BoNT-As 
by the respective market shares, we calculated an average 
annual cost per patient treated with botulinum toxin plus 
 standard therapy of €1,993.08 for upper limb spasticity and 
of €1,425.44 for cervical dystonia.
The decision to involve a group of experts was prompted by 
the need to estimate the average doses of the main botulinum 
Fig. 3 - Budget Impact Analysis (BIA): 
results at 5 years.
TABLE VIII - Sensitivity analysis: Cost Minimization Analysis (CMA)
Difference Dysport® vs Upper limb spasticity Cervical dystonia
Botox® Xeomin® Botox® Xeomin®
Base Case -€226.88 -€330.81 -€79.34 -€149.82
Median dose -€349.69 -€422.11 -€19.41 -€127.58
Median time to next treatment -€215.33 -€341.47 -€68.49 -€144.31
Median cost per vial -€242.23 -€400.59 -€90.80 -€152.05
Dose, time and median cost -€342.22 -€492.16 -€21.32 -€124.96
Ex-factory price per vial -€206.53 -€418.39 -€29.62 -€205.56
TABLE IX - Sensitivity analysis: Budget Impact Analysis (BIA)




Scenario A Scenario A
Base case -€620,428 -€480,918
Median dose -€858,542 -€308,479
Median time to next treatment -€619,379 -€446,594
Median cost per vial -€715,070 -€509,656
Dose, time and median cost -€928,166 -€306,984
Ex-factory price per vial -€695,222 -€493,558
Dysport® substitution effect
 - 8 percentage points per year -€827,237 -€641,224
 - 12 percentage points per year -€1,240,856 -€961,836
points, in ULS the market share and the reduction in toxin ex-
penditure would go up to 93% and €1.2 million, respective-
ly; in CD, the expenditure reduction would be approximately 
€1 million, with an 87% market share.
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toxins type A in the treatment of ULS and CD, and to ensure that 
such doses actually reflected Italian clinical practice, as the in-
formation available in the literature is conflicting and therefore 
not useful in determining a reliable average cost of treatment. 
To ensure that the clinical practice criterion was met as closely 
as possible, each expert was asked to consider for both indi-
cations the data of the last 10 patients, in chronological order, 
who had been referred to the centre and treated with  Dysport®, 
Botox® or Xeomin®, for a total of 30 subjects for each of the two 
indications. For each patient thus identified, they were asked to 
consider, in chronological order, the doses of the last two treat-
ments, for a total of 20 dose measurements (two per patient) 
for each of the toxins considered. The average dose per type of 
toxin (Dysport®, Botox® and Xeomin®) and therapeutic indica-
tion (ULS or CD) indicated by the expert was then calculated as 
an average of the 20 corresponding dosages. 
For the purpose of evaluating the uncertainty of the key 
parameters that determined the results of the base case, an 
in-depth sensitivity analysis was conducted on the dose per 
treatment, the time to next treatment and the average cost 
per vial. In all the individual comparisons conducted by the 
one-way sensitivity analysis or the multivariate analysis, Dys-
port® always determined the lowest average cost of treat-
ment compared to Botox® and Xeomin®. 
In terms of therapeutic indication, upper limb spasticity 
was found to involve a smaller average number of treatments 
(3.5) compared to cervical dystonia (4.2), while in terms of 
botulinum toxins Dysport® determines a slightly smaller num-
ber of administrations compared to the other toxins (ULS: 
Dysport® 3.4, Botox® 3.5 and Xeomin® 3.6; CD:  Dysport® 4.1, 
Botox® 4.2 and Xeomin® 4.3).
A possible limit of the CMA could be the fact that the 
healthcare consumptions of standard therapy are not distin-
guished by specific toxin administered. This choice is justified 
by the considerations set out below. As differences between 
botulinum toxins seem to be attributable to dose rather than 
to their inherent safety and the toxin’s ability to achieve ther-
apeutic response (5, 8-11, 17-20), in our opinion it was rea-
sonable to assume that no difference in efficacy and safety 
profiles corresponds to no difference in consumptions, and 
therefore in the costs determined by the standard therapy 
combined with the three compared botulinum toxins. More-
over, the main objective of the CMA was to estimate the 
 differences, if any, in the costs of treatment of the BoNT-As, 
attributable mainly to the different doses used to achieve the 
therapeutic target.
There are differences in consumption and cost for the 
standard therapy used in ULS or CD. In ULS, the standard 
therapy accounts for approximately 57% of the total costs, 
with a higher use of specialist interventions, whereas in CD 
it accounts for 48% of the total costs, with a higher use of 
rehabilitation therapies.
The results of the budget impact analysis should also be 
read in light of certain observations referring to the epide-
miological data used to build the cohorts of patients treat-
ed with BoNT-A and the substitution rates assumed for 
 Dysport®. In the first case, data from the literature were used 
when available; alternatively, estimates provided by specific 
market surveys were used. As partial justification of pos-
sible estimating errors, it should be noted that any cohorts 
of  patients larger or smaller than those adopted in the base 
case would essentially have increased or reduced, but not 
eliminated, the economic advantage deriving from a greater 
use of Dysport® compared to its competitors. In the second 
case, i.e. with reference to Dysport® substitution rates, as no 
real rates are available, a rate of 6% was assumed in the base 
case, which was then changed in the sensitivity analysis. Here 
again, it is important to point out that Dysport® substitution 
rate selected, it would result, in the long term (five years) in a 
reduction in the pharmaceutical expenditure determined by 
the three BoNT-As. 
Conclusions
The result of the Cost Minimization Analysis has shown 
that Dysport® is the cost-saving therapeutic option, when 
compared in the INHS perspective against Botox® or Xeomin® 
in the treatment of both upper limb spasticity and cervical 
dystonia.
While recognizing the potential limits in determining the 
number of patients treated with botulinum toxins and the 
respective market shares, the subsequent Budget Impact 
Analysis suggests that an increase in patients treated with 
Dysport® would lead to a reduction in the pharmaceutical 
expenditure for BoNT-As incurred by the INHS. Therefore, a 
choice in favour of Dysport® could represent an efficient al-
location of healthcare resources.
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